4-氯-6-氨基喹啉 | 1085192-91-1

• 物质功能分类: 医药中间体 - 喹啉类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 中文名称: 4-氯-6-氨基喹啉
• 英文名称: 4-chloroquinolin-6-amine
• CAS: 1085192-91-1
• 化学式: C₉H₇ClN₂
• 分子量: 178.621
• InChiKey: JQBYZFZHXAYAJF-UHFFFAOYSA-N

物化性质

• 密度：
  1.363

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  12
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  38.9
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 4-Chloroquinolin-6-amine
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 4-Chloroquinolin-6-amine
CAS number: 1085192-91-1

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C9H7ClN2
Molecular weight: 178.6

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen chloride.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  4-氯-6-氨基喹啉 在 盐酸 、 sodium azide 、 sodium nitrite 作用下， 以 乙醇 、 水 为溶剂， 生成 4-((6-azidoquinolin-4-yl)amino)-N-(4-(pyridin-4-ylamino)phenyl)benzamide
  参考文献：
  名称：

  [EN] AKT3 MODULATORS
  [FR] MODULATEURS DE AKT3

  摘要：

  公式Ia、Ib或Ic的化合物已被描述，其中各种取代基在此定义。这些化合物可以在体外或体内调节Akt3的性质或效果，并且也可以单独或与其他药剂结合在预防或治疗各种疾病方面使用。描述了合成这些化合物的方法。还描述了制药组合物以及使用这些化合物或组合物在预防或治疗各种疾病中单独或与其他药剂或组合物结合的方法。

  公开号：

  WO2021226519A1
• 作为产物：
  描述：

  4-氯-6-硝基喹啉 在 tin(ll) chloride 作用下， 生成 4-氯-6-氨基喹啉
  参考文献：
  名称：

  [EN] AKT3 MODULATORS
  [FR] MODULATEURS DE AKT3

  摘要：

  公式Ia、Ib或Ic的化合物已被描述，其中各种取代基在此定义。这些化合物可以在体外或体内调节Akt3的性质或效果，并且也可以单独或与其他药剂结合在预防或治疗各种疾病方面使用。描述了合成这些化合物的方法。还描述了制药组合物以及使用这些化合物或组合物在预防或治疗各种疾病中单独或与其他药剂或组合物结合的方法。

  公开号：

  WO2021226519A1

文献信息

• CYCLOALKYL ACID DERIVATIVE, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL APPLICATION THEREOF
  申请人：SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD.

  公开号：US20160108035A1

  公开（公告）日：2016-04-21

  Cycloalkyl acid derivatives, a preparation method thereof, and a pharmaceutical application thereof are described. In particular, a cycloalkyl acid derivative represented by general formula (I) and a medical salt thereof, a preparation method thereof, and an application of the cycloalkyl acid derivative and the medical salt thereof as URAT1 inhibitors, and particularly as therapeutic agents for diseases related to an abnormal uric acid level are described, wherein definitions of substituent groups in general formula (I) are the same as the definitions in the specification.

  描述了环烷基酸衍生物及其制备方法和药物应用。具体地，描述了一种由通式（I）表示的环烷基酸衍生物及其医用盐，其制备方法，以及将该环烷基酸衍生物和医用盐作为URAT1抑制剂的应用，特别是作为治疗与异常尿酸水平相关疾病的药物。其中，通式（I）中取代基团的定义与说明书中的定义相同。
• 사이클로알킬산 유도체, 그의 제조 방법, 및 그의 약학적 용도
  申请人：SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD. 샹하이 헨그루이 파마수티컬 컴퍼니 리미티드(520080332544)

  公开号：KR20160006207A

  公开（公告）日：2016-01-18

  본 발명은 사이클로알킬산 유도체, 그의 제조 방법 및 그의 약학적 용도에 관한 것이며, 특히 본 발명은 하기 화학식 I에 의해 나타내는 사이클로알킬산 유도체 및 그의 의학적 염, 그의 제조 방법, 및 URAT1 억제제로서 및 특히 이상 요산 수준과 관련된 질병에 대한 치료제로서 상기 사이클로알킬산 유도체 및 그의 의학적 염의 용도에 관한 것이며, 여기에서 화학식 I의 치환체 그룹들의 정의는 명세서에서의 정의와 같다. 화학식 I

  这是一段关于某种环丙基酸衍生物的专利描述，涉及其制备方法和药用用途，特别是涉及由化学式I表示的环丙基酸衍生物及其医药盐、制备方法，以及作为URAT1抑制剂和特别是用于治疗与高尿酸水平相关的疾病的药物的用途。在此，化学式I中的取代基团的定义与规范中的定义相同。 化学式I
• [EN] AKT3 MODULATORS<br/>[FR] MODULATEURS D'AKT3
  申请人：GEORGIAMUNE LLC

  公开号：WO2021226517A1

  公开（公告）日：2021-11-11

  Compounds of Formula la, lb, or Ic,, are described, where the various substituents are defined herein. The compounds can modulate a property or effect of Akt3 in vitro or in vivo, and can also be used, individually or in combination with other agents, in the prevention or treatment of a variety of conditions. Methods for synthesizing the compounds are described. Pharmaceutical compositions and methods of using these compounds or compositions, individually or in combination with other agents or compositions, in the prevention or treatment of a variety of conditions are also described.

  公式Ia、Ib或Ic的化合物被描述，其中各种取代基在此处被定义。这些化合物可以在体外或体内调节Akt3的性质或效应，并且也可以单独或与其他药剂结合在预防或治疗各种疾病方面使用。描述了合成这些化合物的方法。还描述了使用这些化合物或组合物的药物组合物和使用这些化合物或组合物，单独或与其他药剂或组合物结合在预防或治疗各种疾病方面的方法。
• Synthesis of mono-substituted derivatives of 6-aminoquinoline
  作者：Tian Lan、Xian Xia Yuan、Jiang Hong Yu、Chao Jia、Yu Shi Wang、Hui Juan Zhang、Zi Feng Ma、Wei Dong Ye

  DOI：10.1016/j.cclet.2010.10.005

  日期：2011.3

  Abstract Several 6-aminoquinoline derivatives, which could be used in drug design, have been synthesized. The reaction conditions were comparatively studied, and the p -chloroaniline was used as optimum oxidant in Skraup–Doebner–Von Miller reaction. The nitro group was reduced effectively by SnCl 2 with no halo-removed occurred.

  摘要合成了几种可用于药物设计的6-氨基喹啉衍生物。对反应条件进行了比较研究，对氯苯胺被用作Skraup–Doebner–Von Miller反应的最佳氧化剂。SnCl 2有效还原了硝基，没有卤素被去除。
• INDOLE DERIVATIVE-CONTAINING INHIBITOR, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF
  申请人：Shanghai Hansoh Biomedical Co., Ltd.

  公开号：EP3974423A1

  公开（公告）日：2022-03-30

  The present invention relates to an indole derivative-containing inhibitor, a preparation method therefor and an application thereof, and in particular, to a compound as represented by general formula (Ia), a preparation method therefor, a pharmaceutical composition comprising the compound, and the use thereof in treating related diseases such as cancer, inflammation, chronic liver disease, diabetes, cardiovascular disease, and AIDS as a kinase inhibitor, especially as a receptor tyrosine kinase inhibitor (TKI), more specifically, as an EGFR or HER2 inhibitor. The compound exhibits good inhibitory activity in EGFR and HER2 20 exon mutations.

  本发明涉及一种含有吲哚衍生物的抑制剂，其制备方法和应用，特别是一种由一般式（Ia）所代表的化合物，其制备方法，包括该化合物的制药组合物以及其作为激酶抑制剂的用途，特别是作为受体酪氨酸激酶抑制剂（TKI），更具体地作为EGFR或HER2抑制剂，用于治疗癌症、炎症、慢性肝病、糖尿病、心血管疾病和艾滋病等相关疾病。该化合物在EGFR和HER2 20外显子突变中表现出良好的抑制活性。